These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28288113)

  • 1. Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformations.
    Wang X; Charng WL; Chen CA; Rosenfeld JA; Al Shamsi A; Al-Gazali L; McGuire M; Mew NA; Arnold GL; Qu C; Ding Y; Muzny DM; Gibbs RA; Eng CM; Walkiewicz M; Xia F; Plon SE; Lupski JR; Schaaf CP; Yang Y
    Nat Genet; 2017 Apr; 49(4):613-617. PubMed ID: 28288113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expanding clinical phenotype of germline ABL1-associated congenital heart defects and skeletal malformations syndrome.
    Chen CA; Crutcher E; Gill H; Nelson TN; Robak LA; Jongmans MCJ; Pfundt R; Prasad C; Berard RA; Fannemel M; Frengen E; Misceo D; Ramsey K; Yang Y; Schaaf CP; Wang X
    Hum Mutat; 2020 Oct; 41(10):1738-1744. PubMed ID: 32643838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
    Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic variants causing ABL1 malformation syndrome cluster in a myristoyl-binding pocket and increase tyrosine kinase activity.
    Blakes AJM; Gaul E; Lam W; Shannon N; Knapp KM; Bicknell LS; Jackson MR; Wade EM; Robertson S; White SM; Heller R; Chase A; Baralle D; Douglas AGL
    Eur J Hum Genet; 2021 Apr; 29(4):593-603. PubMed ID: 33223528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The smallest de novo deletion of 20q11.21-q11.23 in a girl with feeding problems, retinal dysplasia, and skeletal abnormalities.
    Posmyk R; Leśniewicz R; Gogiel M; Chorąży M; Bakunowicz-Łazarczyk A; Sielicka D; Vermeesch J; Nowakowska BA
    Am J Med Genet A; 2014 Apr; 164A(4):1056-61. PubMed ID: 24459047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient.
    Zámečníkova A; Al Bahar S; Pandita R
    Hematology; 2012 Nov; 17(6):321-4. PubMed ID: 22989955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein.
    Brown S; Hutchinson CV; Aspinall-O'Dea M; Whetton AD; Johnson SM; Rees-Unwin K; Burthem J
    Eur J Haematol; 2014 Aug; 93(2):96-102. PubMed ID: 24617663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.
    Cho YU; Kim SO; Chi HS; Park SJ; Jang S; Park CJ; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ; Hong SP
    Int J Lab Hematol; 2013 Dec; 35(6):589-600. PubMed ID: 23575252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Philadelphia chromosome in leukemogenesis.
    Kang ZJ; Liu YF; Xu LZ; Long ZJ; Huang D; Yang Y; Liu B; Feng JX; Pan YJ; Yan JS; Liu Q
    Chin J Cancer; 2016 May; 35():48. PubMed ID: 27233483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
    Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
    Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C
    Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene.
    Makita Y; Narumi Y; Yoshida M; Niihori T; Kure S; Fujieda K; Matsubara Y; Aoki Y
    J Pediatr Hematol Oncol; 2007 May; 29(5):287-90. PubMed ID: 17483702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis.
    Jain PP; Parihar M; Ahmed R; Abraham A; Vishwabandya A; George B; Mathews V; Srivastava A; Srivastava VM
    Indian J Pathol Microbiol; 2012; 55(3):347-51. PubMed ID: 23032829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.